Hypertension and Valvular Heart Disease: An Overview of a Complex and Clinically Meaningful Relationship

Roxana Oana Darabont1,2, Diana Mihalcea1,2, Dragos Vinereanu1,2

  • 1Cardiology and Cardiovascular Surgery Department, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Life (Basel, Switzerland)
|January 28, 2026
PubMed

Insights

Hypertension (HTN) significantly impacts valvular heart disease (VHD) by stressing valves and altering blood flow. Managing blood pressure is crucial for VHD patients, though specific targets for mitral regurgitation require further research.

Area of Science:

  • Cardiology
  • Hypertension Research
  • Valvular Heart Disease Studies

Background:

  • The link between hypertension (HTN) and valvular heart disease (VHD) is increasingly recognized.
  • Approximately 45% of VHD patients also have HTN, with this association strengthening with age.
  • HTN exacerbates VHD through mechanical valve stress and altered hemodynamics.

Purpose of the Study:

  • To review the impact of HTN on VHD development and progression.
  • To examine HTN's effect on VHD patient prognosis.
  • To discuss current data on blood pressure management in VHD.

Main Methods:

  • Literature review of studies on hypertension and valvular heart disease.
  • Analysis of epidemiological data linking blood pressure to VHD risk.
  • Synthesis of current guidelines and research on blood pressure management strategies.

Main Results:

  • Elevated blood pressure significantly increases the risk of aortic valvular disease and mitral regurgitation.
  • A 20 mmHg increase in systolic blood pressure triples the risk of these valvular conditions.
  • HTN contributes to VHD onset and progression via mechanical stress and hemodynamic changes.

Conclusions:

  • Hypertension is a key factor in the development and worsening of valvular heart disease.
  • Further research is needed to establish optimal blood pressure targets and drug therapies for mitral regurgitation.
  • Understanding the HTN-VHD relationship is critical for improving patient outcomes.

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.4K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
570
Overview of the Heart01:07

Overview of the Heart

The heart, a muscular organ located in the chest, functions as the body's pump, circulating blood through the vascular system. It has four chambers: two atria on top and two ventricles below. The right atrium receives deoxygenated blood from the body and passes it to the right ventricle, which pumps it to the lungs for oxygenation. The left atrium receives oxygenated blood from the lungs and transfers it to the left ventricle, which pumps it to the rest of the body.
The heart's structure...
13.6K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.0K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Complexation Equilibria: Overview01:23

Complexation Equilibria: Overview

Complexation reactions take place when dative or coordinate covalent bonds form between metal ions and ligands. The compounds formed in these reactions are called coordination compounds. The number of bonds formed between the metal ion and the ligands is called its coordination number. Generally, most metal ions in an aqueous solution are solvated by water molecules and thus exist as aqua complexes.
The equilibrium constant of the complexation reaction is represented as the formation constant...
1.4K